Vendor Intelligence Report: Peptide Technologies

Published 13 Jun 2026. 23-page investigative report on who is behind Peptide Technologies: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Peptide Technologies is a product-specific call, not a blanket verdict. Across 11 Finnrick lab tests, Peptide Technologies passes 7 and fails 4, for an overall pass rate of 64%. Semaglutide is the cleanest relative signal; BPC-157 is the weak point; PT-141 remains thin and mixed. Ratings also look less comfortable under stricter dose/fill views, making exact-lot verification more important than vendor slogans.

The sharper red flags sit in the trust infrastructure. Court coverage documents a Mastercard MATCH listing under a standards-violation designation, a terminated processing relationship, and dismissal of Peptide Tech's bank suit. That is not an assay failure, but it affects buyer leverage when checkout shifts toward P2P apps, eCheck, or crypto.

The report separates COA visibility from accreditation claims. Peptide Technologies has a large Freedom Diagnostics COA footprint, but the advertised ISO 17025 framing is not corroborated by the accreditation checks in the file. Domain, trademark, court, and hosting records point to a young 2024 launch, a Wyoming mail/registered-agent layer, and a later offshore .is presentation while claimed Texas and California operating sites remain unresolved.

Marketing evidence is narrower but still relevant: a July 2024 Reddit comeback post carried an affiliate-style tracking link in a moderator/community context, while the broader X and web sweep found mostly coupon aggregators rather than a proven influencer network. The directional read is comparatively defensible for semaglutide, cautionary for PT-141, and weak for BPC-157 unless the exact lot is independently checked.

Inside the full report:

  • Full Finnrick product-by-methodology data, divergence charts, and BPC-157 trajectory detail
  • MATCH listing and Avidia Bank litigation analysis from court and National Law Review records
  • ISO 17025 verification checks for Freedom Diagnostics, Janoshik, and Chromate
  • Domain/Wayback timeline from the Shopify ISO 9001 storefront to the offshore .is presentation
  • Trademark, entity, Wyoming CMRA address, and named USPTO filer analysis
  • Reddit affiliate capture, coupon-site sweep, and disambiguation from similarly named companies

Risk assessment

  • Unsubstantiated ISO 17025 safety claims — high: Peptide Technologies advertises ISO 17025 verification, but supplied lab and accreditor checks found no ISO 17025 accreditation for Freedom Diagnostics, Janoshik, or Chromate; Freedom’s public claim is ISO 9001.
  • Payment-processing instability — high: Court-reported Mastercard MATCH listing for “violation of standards” and dismissal of the Avidia Bank suit leave the vendor reliant on weaker-recoursed rails such as Cash App, Venmo, Zelle, eCheck, and crypto.
  • Product-specific quality inconsistency — medium: Finnrick shows BPC-157 as the principal concern at 44.98% with 2 pass / 3 fail; PT-141 is thin and mixed at 57.98% with 1 pass / 1 fail, while semaglutide is materially stronger.
  • Undisclosed affiliate-promotion risk — medium: A July 2024 r/Peptidesource post by u/Financial_Emu_1698 used an affiliate-style tracking link without clear disclosure; the broader X/web sweep found mostly coupon aggregators and no X promoter network.
  • Brand-confusion and authenticity-verification risk — medium: The brand uses both .co and .is domains while unrelated Peptide Tech Labs and Regenerex / Peptide Technologies references appear online; no complete authorized-channel or anti-counterfeit framework was identified.